{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:28:58Z","timestamp":1789504138659,"version":"build-2803163510"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02807-0","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:15:48Z","timestamp":1748942148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genetic, epigenetic, and molecular determinants of multiple myeloma and precursor plasma cell disorders: a pathophysiological overview"],"prefix":"10.1007","volume":"42","author":[{"given":"Henry","family":"Sutanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debi Yulia","family":"Sandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardea","family":"Safira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galih Januar","family":"Adytia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alief","family":"Waitupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradana Zaky","family":"Romadhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2807_CR1","volume-title":"Multiple Myeloma","author":"SA Albagoush","year":"2025","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma. Treasure Island (FL): In StatPearls; StatPearls Publishing; 2025."},{"key":"2807_CR2","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2022.110","author":"M Moscvin","year":"2023","unstructured":"Moscvin M, Evans B, Bianchi G. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions. J Cancer Metastasis Treat. 2023. https:\/\/doi.org\/10.20517\/2394-4722.2022.110.","journal-title":"J Cancer Metastasis Treat"},{"key":"2807_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood.2024027065","volume":"145","author":"IM Ghobrial","year":"2025","unstructured":"Ghobrial IM, Chabrun F. Is it time to screen for multiple myeloma? Blood. 2025;145:253\u20135. https:\/\/doi.org\/10.1182\/blood.2024027065.","journal-title":"Blood"},{"key":"2807_CR4","volume-title":"Monoclonal Gammopathy of Undetermined Significance","author":"H Kaseb","year":"2025","unstructured":"Kaseb H, Annamaraju P, Babiker HM. Monoclonal Gammopathy of Undetermined Significance. Treasure Island (FL): In StatPearls; StatPearls Publishing; 2025."},{"key":"2807_CR5","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","volume":"117","author":"N Korde","year":"2011","unstructured":"Korde N, Kristinsson SY, Landgren O. Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM): novel biological insights and development of early treatment strategies. Blood. 2011;117:5573\u201381. https:\/\/doi.org\/10.1182\/blood-2011-01-270140.","journal-title":"Blood"},{"key":"2807_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ijlh.12504","volume":"38","author":"NWCJ van de Donk","year":"2016","unstructured":"van de Donk NWCJ, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol. 2016;38:110\u201322. https:\/\/doi.org\/10.1111\/ijlh.12504.","journal-title":"Int J Lab Hematol"},{"key":"2807_CR7","doi-asserted-by":"crossref","unstructured":"Shain, K.H.; Dalton, W.S. Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy. In Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics; Tao, J., Sotomayor, E., Eds.; Springer Netherlands: Dordrecht, 2012; pp. 53\u201382 ISBN 978\u201394\u2013007\u20135027\u20132.","DOI":"10.1007\/978-94-007-5028-9_4"},{"key":"2807_CR8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3324\/haematol.2009.008979","volume":"94","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, Goldin LR, Bjorkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica. 2009;94:1581\u20139. https:\/\/doi.org\/10.3324\/haematol.2009.008979.","journal-title":"Haematologica"},{"key":"2807_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00277-022-04856-1","volume":"101","author":"P Hagen","year":"2022","unstructured":"Hagen P, Sellin M, Berg S, Zhang J. Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. Ann Hematol. 2022;101:1407\u201320. https:\/\/doi.org\/10.1007\/s00277-022-04856-1.","journal-title":"Ann Hematol"},{"key":"2807_CR10","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3390\/cancers14112597","volume":"14","author":"A Allegra","year":"2022","unstructured":"Allegra A, Casciaro M, Barone P, Musolino C, Gangemi S. Epigenetic crosstalk between malignant plasma cells and the tumour microenvironment in multiple myeloma. Cancers. 2022;14:2597. https:\/\/doi.org\/10.3390\/cancers14112597.","journal-title":"Cancers"},{"key":"2807_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ncrna9060068","volume":"9","author":"NH Ismail","year":"2023","unstructured":"Ismail NH, Mussa A, Al-Khreisat MJ, Mohamed Yusoff S, Husin A, Al-Jamal HAN, Johan MF, Islam MA. Dysregulation of non-coding RNAs: roles of miRNAs and lncRNAs in the pathogenesis of multiple myeloma. ncRNA. 2023;9:68. https:\/\/doi.org\/10.3390\/ncrna9060068.","journal-title":"ncRNA"},{"key":"2807_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3389\/fonc.2018.00566","volume":"8","author":"E De Smedt","year":"2018","unstructured":"De Smedt E, Lui H, Maes K, De Veirman K, Menu E, Vanderkerken K, De Bruyne E. The epigenome in multiple myeloma: impact on tumor cell plasticity and drug response. Front Oncol. 2018;8:566. https:\/\/doi.org\/10.3389\/fonc.2018.00566.","journal-title":"Front Oncol"},{"key":"2807_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","volume":"23","author":"S Manier","year":"2016","unstructured":"Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr Opin Hematol. 2016;23:426\u201333. https:\/\/doi.org\/10.1097\/MOH.0000000000000259.","journal-title":"Curr Opin Hematol"},{"key":"2807_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4252\/wjsc.v15.i5.421","volume":"15","author":"D Garc\u00eda-S\u00e1nchez","year":"2023","unstructured":"Garc\u00eda-S\u00e1nchez D, Gonz\u00e1lez-Gonz\u00e1lez A, Alfonso-Fern\u00e1ndez A, Del Dujo-Guti\u00e9rrez M, P\u00e9rez-Campo FM. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. World J Stem Cells. 2023;15:421\u201337. https:\/\/doi.org\/10.4252\/wjsc.v15.i5.421.","journal-title":"World J Stem Cells"},{"key":"2807_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12185-011-0949-x","volume":"94","author":"M Abe","year":"2011","unstructured":"Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94:334\u201343. https:\/\/doi.org\/10.1007\/s12185-011-0949-x.","journal-title":"Int J Hematol"},{"key":"2807_CR16","doi-asserted-by":"publisher","first-page":"1243997","DOI":"10.3389\/fimmu.2023.1243997","volume":"14","author":"S Forster","year":"2023","unstructured":"Forster S, Radpour R, Ochsenbein AF. Molecular and immunological mechanisms of clonal evolution in multiple myeloma. Front Immunol. 2023;14:1243997. https:\/\/doi.org\/10.3389\/fimmu.2023.1243997.","journal-title":"Front Immunol"},{"key":"2807_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2217\/ijh-2021-0017","volume":"11","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan M, Nasr Lewis, Kassab Joseph, Saba Ludovic, Ghossein Myriam, Yaghi Marita, Dominguez Barbara, Chaulagain CP. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy. Int J Hematol Oncol. 2022;11:39. https:\/\/doi.org\/10.2217\/ijh-2021-0017.","journal-title":"Int J Hematol Oncol"},{"key":"2807_CR18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2003-07-2187","volume":"103","author":"S Abroun","year":"2004","unstructured":"Abroun S, Ishikawa H, Tsuyama N, Liu S, Li F-J, Otsuyama K, Zheng X, Obata M, Kawano MM. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor \u03b1. Blood. 2004;103:2291\u20138. https:\/\/doi.org\/10.1182\/blood-2003-07-2187.","journal-title":"Blood"},{"key":"2807_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12026-014-8528-x","volume":"59","author":"TR Rosean","year":"2014","unstructured":"Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014;59:188\u2013202. https:\/\/doi.org\/10.1007\/s12026-014-8528-x.","journal-title":"Immunol Res"},{"key":"2807_CR20","unstructured":"Duffy, A.M.; Bouchier-Hayes, D.J.; Harmey, J.H. Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF. In Madame Curie Bioscience Database [Internet]; Landes Bioscience, 2013."},{"key":"2807_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity. 2019;50:924\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024.","journal-title":"Immunity"},{"key":"2807_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8:7. https:\/\/doi.org\/10.1038\/s41408-017-0037-4.","journal-title":"Blood Cancer J"},{"key":"2807_CR23","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.3390\/ijms21145169","volume":"21","author":"H Kitaura","year":"2020","unstructured":"Kitaura H, Marahleh A, Ohori F, Noguchi T, Shen W-R, Qi J, Nara Y, Pramusita A, Kinjo R, Mizoguchi I. Osteocyte-related cytokines regulate osteoclast formation and bone resorption. Int J Mol Sci. 2020;21:5169. https:\/\/doi.org\/10.3390\/ijms21145169.","journal-title":"Int J Mol Sci"},{"key":"2807_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","volume":"40","author":"T Ono","year":"2020","unstructured":"Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regener. 2020;40:2. https:\/\/doi.org\/10.1186\/s41232-019-0111-3.","journal-title":"Inflamm Regener"},{"key":"2807_CR25","doi-asserted-by":"publisher","first-page":"7597","DOI":"10.3390\/ijms21207597","volume":"21","author":"J Jann","year":"2020","unstructured":"Jann J, Gascon S, Roux S, Faucheux N. Influence of the TGF-\u03b2 superfamily on osteoclasts\/osteoblasts balance in physiological and pathological bone conditions. Int J Mol Sci. 2020;21:7597. https:\/\/doi.org\/10.3390\/ijms21207597.","journal-title":"Int J Mol Sci"},{"key":"2807_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcancer.2017.09.007","volume":"51","author":"M Alzrigat","year":"2018","unstructured":"Alzrigat M, P\u00e1rraga AA, Jernberg-Wiklund H. Epigenetics in multiple myeloma: from mechanisms to therapy. Semin Cancer Biol. 2018;51:101\u201315. https:\/\/doi.org\/10.1016\/j.semcancer.2017.09.007.","journal-title":"Semin Cancer Biol"},{"key":"2807_CR27","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.3390\/jcm12134440","volume":"12","author":"V Gerov","year":"2023","unstructured":"Gerov V, Gerova D, Micheva I, Nikolova M, Mihaylova G, Galunska B. Dynamics of bone disease biomarkers dickkopf-1 and sclerostin in patients with multiple myeloma. J Clin Med. 2023;12:4440. https:\/\/doi.org\/10.3390\/jcm12134440.","journal-title":"J Clin Med"},{"key":"2807_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Sig Transduct Target Ther. 2023;8:1\u201339. https:\/\/doi.org\/10.1038\/s41392-023-01460-1.","journal-title":"Sig Transduct Target Ther"},{"key":"2807_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fonc.2013.00211","volume":"3","author":"S Azzi","year":"2013","unstructured":"Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211. https:\/\/doi.org\/10.3389\/fonc.2013.00211.","journal-title":"Front Oncol"},{"key":"2807_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y. Macrophages in immunoregulation and therapeutics. Sig Transduct Target Ther. 2023;8:1\u201335. https:\/\/doi.org\/10.1038\/s41392-023-01452-1.","journal-title":"Sig Transduct Target Ther"},{"key":"2807_CR31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11:1371. https:\/\/doi.org\/10.3389\/fimmu.2020.01371.","journal-title":"Front Immunol"},{"key":"2807_CR32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","volume":"10","author":"A Bruno","year":"2019","unstructured":"Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression. Front Immunol. 2019;10:771. https:\/\/doi.org\/10.3389\/fimmu.2019.00771.","journal-title":"Front Immunol"},{"key":"2807_CR33","doi-asserted-by":"publisher","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S, Nayak D, Kaushik S, Das T, Sa G. Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. 2023;14:1295257. https:\/\/doi.org\/10.3389\/fimmu.2023.1295257.","journal-title":"Front Immunol"},{"key":"2807_CR34","doi-asserted-by":"publisher","first-page":"1026954","DOI":"10.3389\/fimmu.2022.1026954","volume":"13","author":"C Kerneur","year":"2022","unstructured":"Kerneur C, Cano CE, Olive D. Major pathways involved in macrophage polarization in cancer. Front Immunol. 2022;13:1026954. https:\/\/doi.org\/10.3389\/fimmu.2022.1026954.","journal-title":"Front Immunol"},{"key":"2807_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12:99. https:\/\/doi.org\/10.1186\/s40164-023-00456-5.","journal-title":"Exp Hematol Oncol"},{"key":"2807_CR36","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/ijms24065730","volume":"24","author":"A Kulikowska de Na\u0142\u0119cz","year":"2023","unstructured":"Kulikowska de Na\u0142\u0119cz A, Ciszak L, Usnarska-Zubkiewicz L, Pawlak E, Frydecka I, Szmyrka M, Kosmaczewska A. Inappropriate expression of PD-1 and CTLA-4 checkpoints in myeloma patients is more pronounced at diagnosis: implications for time to progression and response to therapeutic checkpoint inhibitors. Int J Mol Sci. 2023;24:5730. https:\/\/doi.org\/10.3390\/ijms24065730.","journal-title":"Int J Mol Sci"},{"key":"2807_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116203","volume":"171","author":"J-W Cui","year":"2024","unstructured":"Cui J-W, Li Y, Yang Y, Yang H-K, Dong J-M, Xiao Z-H, He X, Guo J-H, Wang R-Q, Dai B, et al. Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape. Biomed Pharmacother. 2024;171: 116203. https:\/\/doi.org\/10.1016\/j.biopha.2024.116203.","journal-title":"Biomed Pharmacother"},{"key":"2807_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","volume":"14","author":"H Sutanto","year":"2024","unstructured":"Sutanto H, Safira A, Fetarayani D. From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events. Asia Pac Allergy. 2024;14:124\u201338. https:\/\/doi.org\/10.5415\/apallergy.0000000000000146.","journal-title":"Asia Pac Allergy"},{"key":"2807_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","volume":"49","author":"JA Clara","year":"2022","unstructured":"Clara JA, Childs RW. Harnessing natural killer cells for the treatment of multiple myeloma. Semin Oncol. 2022;49:69\u201385. https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.004.","journal-title":"Semin Oncol"},{"key":"2807_CR40","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1111\/cas.15800","volume":"114","author":"J Jiang","year":"2023","unstructured":"Jiang J, Xiang J, Chen M, Wan Y, Zhong L, Han X, Chen X, Wang J, Xiao F, Liu J, et al. Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma. Cancer Sci. 2023;114:2750\u201360. https:\/\/doi.org\/10.1111\/cas.15800.","journal-title":"Cancer Sci"},{"key":"2807_CR41","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/s41598-018-23943-w","volume":"8","author":"P Shinde","year":"2018","unstructured":"Shinde P, Fernandes S, Melinkeri S, Kale V, Limaye L. Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy. Sci Rep. 2018;8:5705. https:\/\/doi.org\/10.1038\/s41598-018-23943-w.","journal-title":"Sci Rep"},{"key":"2807_CR42","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1074\/jbc.M116.733030","volume":"292","author":"M Furukawa","year":"2017","unstructured":"Furukawa M, Ohkawara H, Ogawa K, Ikeda K, Ueda K, Shichishima-Nakamura A, Ito E, Imai J, Yanagisawa Y, Honma R, et al. Autocrine and paracrine interactions between multiple myeloma cells and bone marrow stromal cells by growth arrest-specific gene 6 cross-talk with interleukin-6. J Biol Chem. 2017;292:4280\u201392. https:\/\/doi.org\/10.1074\/jbc.M116.733030.","journal-title":"J Biol Chem"},{"key":"2807_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2019.100040","volume":"5","author":"R Spelat","year":"2020","unstructured":"Spelat R, Ferro F, Contessotto P, Warren NJ, Marsico G, Armes SP, Pandit A. A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells. Materials Today Bio. 2020;5: 100040. https:\/\/doi.org\/10.1016\/j.mtbio.2019.100040.","journal-title":"Materials Today Bio"},{"key":"2807_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5:25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w.","journal-title":"Mol Biomed"},{"key":"2807_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fendo.2018.00788","volume":"9","author":"D Harmer","year":"2019","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2019;9:788. https:\/\/doi.org\/10.3389\/fendo.2018.00788.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2807_CR46","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2017.6528","volume":"14","author":"J Pan","year":"2017","unstructured":"Pan J, Sun Y, Zhang N, Li J, Ta F, Wei W, Yu S, Ai L. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett. 2017;14:2657\u201362. https:\/\/doi.org\/10.3892\/ol.2017.6528.","journal-title":"Oncol Lett"},{"key":"2807_CR47","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/blood-2002-09-2813","volume":"101","author":"Y-T Tai","year":"2003","unstructured":"Tai Y-T, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3\u2013kinase\/AKT\/NF-\u03baB signaling. Blood. 2003;101:2762\u20139. https:\/\/doi.org\/10.1182\/blood-2002-09-2813.","journal-title":"Blood"},{"key":"2807_CR48","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1182\/blood.V106.11.1564.1564","volume":"106","author":"S Chen-Kiang","year":"2005","unstructured":"Chen-Kiang S, Ely S, Di Liberto M, Wu K, Shaughnessy J, Moore M, Niesvizky R, Hatada E. Aberrant autocrine and paracrine CD40L signaling promotes primary myeloma cell survival and attenuates bortezomib-induced apoptosis. Blood. 2005;106:1564. https:\/\/doi.org\/10.1182\/blood.V106.11.1564.1564.","journal-title":"Blood"},{"key":"2807_CR49","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1182\/blood-2014-03-557298","volume":"124","author":"Z Liu","year":"2014","unstructured":"Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, et al. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood. 2014;124:2061\u201371. https:\/\/doi.org\/10.1182\/blood-2014-03-557298.","journal-title":"Blood"},{"key":"2807_CR50","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.V118.21.2904.2904","volume":"118","author":"Z Liu","year":"2011","unstructured":"Liu Z, Zheng Y, Li H, Lu Y, Weber DM, He J, Kwak LW, Yi Q. Autocrine sonic hedgehog protects multiple myeloma cells from apoptosis and enhances drug resistance. Blood. 2011;118:2904\u20132904. https:\/\/doi.org\/10.1182\/blood.V118.21.2904.2904.","journal-title":"Blood"},{"key":"2807_CR51","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1038\/s41375-024-02391-8","volume":"38","author":"J Sun","year":"2024","unstructured":"Sun J, Corradini S, Azab F, Shokeen M, Muz B, Miari KE, Maksimos M, Diedrich C, Asare O, Alhallak K, et al. IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma. Leukemia. 2024;38:2355\u201365. https:\/\/doi.org\/10.1038\/s41375-024-02391-8.","journal-title":"Leukemia"},{"key":"2807_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/tcmj.tcmj_141_20","volume":"33","author":"C-D Liu","year":"2021","unstructured":"Liu C-D, Chang C-C, Huang W-H. The perspectives of interleukin-10 in the pathogenesis and therapeutics of multiple myeloma. Tzu Chi Med J. 2021;33:257. https:\/\/doi.org\/10.4103\/tcmj.tcmj_141_20.","journal-title":"Tzu Chi Med J"},{"key":"2807_CR53","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/cancers10060206","volume":"10","author":"Y-H Huang","year":"2018","unstructured":"Huang Y-H, Molavi O, Alshareef A, Haque M, Wang Q, Chu MP, Venner CP, Sandhu I, Peters AC, Lavasanifar A, et al. Constitutive activation of STAT3 in myeloma cells cultured in a three-dimensional. Reconstructed Bone Marrow Model Cancers (Basel). 2018;10:206. https:\/\/doi.org\/10.3390\/cancers10060206.","journal-title":"Reconstructed Bone Marrow Model Cancers (Basel)"},{"key":"2807_CR54","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1182\/blood-2003-12-4386","volume":"104","author":"EPM Tjin","year":"2004","unstructured":"Tjin EPM, Derksen PWB, Kataoka H, Spaargaren M, Pals ST. Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood. 2004;104:2172\u20135. https:\/\/doi.org\/10.1182\/blood-2003-12-4386.","journal-title":"Blood"},{"key":"2807_CR55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/biomedicines3010149","volume":"3","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Jain RK, Zhu M. Recent progress and advances in HGF\/MET-targeted therapeutic agents for cancer treatment. Biomedicines. 2015;3:149\u201381. https:\/\/doi.org\/10.3390\/biomedicines3010149.","journal-title":"Biomedicines"},{"key":"2807_CR56","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbcan.2010.07.006","volume":"1806","author":"K Mahtouk","year":"2010","unstructured":"Mahtouk K, Tjin EPM, Spaargaren M, Pals ST. The HGF\/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochimica et Biophysica Acta BBA \u2013 Rev Cancer. 2010;1806:208\u201319. https:\/\/doi.org\/10.1016\/j.bbcan.2010.07.006.","journal-title":"Biochimica et Biophysica Acta BBA \u2013 Rev Cancer"},{"key":"2807_CR57","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1073\/pnas.1618650114","volume":"114","author":"H Van Andel","year":"2017","unstructured":"Van Andel H, Ren Z, Koopmans I, Joosten SPJ, Kocemba KA, De Lau W, Kersten MJ, De Bruin AM, Guikema JEJ, Clevers H, et al. Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins. Proc Natl Acad Sci USA. 2017;114:376\u201381. https:\/\/doi.org\/10.1073\/pnas.1618650114.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2807_CR58","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","volume":"33","author":"H van Andel","year":"2019","unstructured":"van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33:1063\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0404-1.","journal-title":"Leukemia"},{"key":"2807_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591342","volume":"10","author":"S Wu","year":"2021","unstructured":"Wu S, Kuang H, Ke J, Pi M, Yang D-H. Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma. Front Oncol. 2021;10: 591342. https:\/\/doi.org\/10.3389\/fonc.2020.591342.","journal-title":"Front Oncol"},{"key":"2807_CR60","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2019.05","author":"D Rizzieri","year":"2019","unstructured":"Rizzieri D, Paul B, Kang Y. Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. JCMT. 2019. https:\/\/doi.org\/10.20517\/2394-4722.2019.05.","journal-title":"JCMT"},{"key":"2807_CR61","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ajh.26577","volume":"97","author":"LA Evans","year":"2022","unstructured":"Evans LA, Anderson EA, Jessen E, Nandakumar B, Atilgan E, Jevremovic D, Hitosugi T, Fonseca R, Kumar SK, Gonsalves WI. Overexpression of the energy metabolism transcriptome within clonal plasma cells is associated with the pathogenesis and outcomes of patients with multiple myeloma. American J Hematol. 2022;97:895\u2013902. https:\/\/doi.org\/10.1002\/ajh.26577.","journal-title":"American J Hematol"},{"key":"2807_CR62","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers14081905","volume":"2022","author":"JSL Lim","year":"1905","unstructured":"Lim JSL, Chong PSY, Chng W-J. Metabolic vulnerabilities in multiple myeloma. Cancers. 1905;2022:14. https:\/\/doi.org\/10.3390\/cancers14081905.","journal-title":"Cancers"},{"key":"2807_CR63","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1182\/blood-2019-129818","volume":"134","author":"S Okabe","year":"2019","unstructured":"Okabe S, Tanaka Y, Moriyama M, Gotoh A. Targeting glycolysis in multiple myeloma: novel strategies in the treatment of proteasome inhibitor resistant in hypoxic conditions. Blood. 2019;134:4344. https:\/\/doi.org\/10.1182\/blood-2019-129818.","journal-title":"Blood"},{"key":"2807_CR64","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/cancers13030396","volume":"13","author":"TA Bloedjes","year":"2021","unstructured":"Bloedjes TA, De Wilde G, Guikema JEJ. Metabolic effects of recurrent genetic aberrations in multiple myeloma. Cancers. 2021;13:396. https:\/\/doi.org\/10.3390\/cancers13030396.","journal-title":"Cancers"},{"key":"2807_CR65","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/cancers15061682","volume":"15","author":"P Weir","year":"2023","unstructured":"Weir P, Donaldson D, McMullin MF, Crawford L. Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance. Cancers. 2023;15:1682. https:\/\/doi.org\/10.3390\/cancers15061682.","journal-title":"Cancers"},{"key":"2807_CR66","doi-asserted-by":"publisher","first-page":"1155621","DOI":"10.3389\/fonc.2023.1155621","volume":"13","author":"M Matamala Montoya","year":"2023","unstructured":"Matamala Montoya M, Van Slobbe GJJ, Chang J-C, Zaal EA, Berkers CR. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment. Front Oncol. 2023;13:1155621. https:\/\/doi.org\/10.3389\/fonc.2023.1155621.","journal-title":"Front Oncol"},{"key":"2807_CR67","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41418-022-01022-y","volume":"29","author":"L Sainero-Alcolado","year":"2022","unstructured":"Sainero-Alcolado L, Lia\u00f1o-Pons J, Ruiz-P\u00e9rez MV, Arsenian-Henriksson M. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022;29:1304\u201317. https:\/\/doi.org\/10.1038\/s41418-022-01022-y.","journal-title":"Cell Death Differ"},{"key":"2807_CR68","doi-asserted-by":"publisher","first-page":"11430","DOI":"10.3390\/ijms222111430","volume":"22","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA. Metabolic disorders in multiple myeloma. IJMS. 2021;22:11430. https:\/\/doi.org\/10.3390\/ijms222111430.","journal-title":"IJMS"},{"key":"2807_CR69","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1182\/blood-2023-186637","volume":"142","author":"M Chiu","year":"2023","unstructured":"Chiu M, Griffini E, Toscani D, Taurino G, Maccari C, Andreoli R, D\u2019Amico G, Giuliani N, Bussolati O. Glutamine addiction of multiple myeloma cells reprograms mesenchymal stromal cell enzymes and transporters towards a pro-tumor phenotype. Blood. 2023;142:4680\u20134680. https:\/\/doi.org\/10.1182\/blood-2023-186637.","journal-title":"Blood"},{"key":"2807_CR70","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1182\/blood.V126.23.3059.3059","volume":"126","author":"DT Vogl","year":"2015","unstructured":"Vogl DT, Younes A, Stewart K, Orford KW, Bennett M, Siegel D, Berdeja JG. Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma. Blood. 2015;126:3059. https:\/\/doi.org\/10.1182\/blood.V126.23.3059.3059.","journal-title":"Blood"},{"key":"2807_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.20517\/cdr.2024.35","volume":"7","author":"S Okabe","year":"2024","unstructured":"Okabe S, Tanaka Y, Moriyama M, Gotoh A. Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects. Cancer Drug Resist. 2024;7:25. https:\/\/doi.org\/10.20517\/cdr.2024.35.","journal-title":"Cancer Drug Resist"},{"key":"2807_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141851","author":"PS Rana","year":"2023","unstructured":"Rana PS, Goparaju K, Driscoll JJ. Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1141851.","journal-title":"Front Oncol"},{"key":"2807_CR73","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/cancers16203513","volume":"16","author":"C-F Chiu","year":"2024","unstructured":"Chiu C-F, Guerrero JJG, Regalado RRH, Zhou J, Notarte KI, Lu Y-W, Encarnacion PC, Carles CDD, Octavo EM, Limbaroc DCI, et al. Insights into metabolic reprogramming in tumor evolution and therapy. Cancers. 2024;16:3513. https:\/\/doi.org\/10.3390\/cancers16203513.","journal-title":"Cancers"},{"key":"2807_CR74","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/ijms19041200","volume":"19","author":"C El Arfani","year":"2018","unstructured":"El Arfani C, De Veirman K, Maes K, De Bruyne E, Menu E. Metabolic features of multiple myeloma. IJMS. 2018;19:1200. https:\/\/doi.org\/10.3390\/ijms19041200.","journal-title":"IJMS"},{"key":"2807_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10173","volume":"3","author":"M Masarwi","year":"2019","unstructured":"Masarwi M, DeSchiffart A, Ham J, Reagan MR. Multiple myeloma and fatty acid metabolism. JBMR Plus. 2019;3: e10173. https:\/\/doi.org\/10.1002\/jbm4.10173.","journal-title":"JBMR Plus"},{"key":"2807_CR76","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2014","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors \u2013 molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18:947\u201361. https:\/\/doi.org\/10.1111\/jcmm.12279.","journal-title":"J Cell Mol Med"},{"key":"2807_CR77","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","volume":"33","author":"AK Dutta","year":"2019","unstructured":"Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, Hewett DR, Zannettino ACW. Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33:457\u201368. https:\/\/doi.org\/10.1038\/s41375-018-0206-x.","journal-title":"Leukemia"},{"key":"2807_CR78","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384\u201390. https:\/\/doi.org\/10.1038\/leu.2013.199.","journal-title":"Leukemia"},{"key":"2807_CR79","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","volume":"102","author":"A Mikulasova","year":"2017","unstructured":"Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, et al. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017;102:1617\u201325. https:\/\/doi.org\/10.3324\/haematol.2017.163766.","journal-title":"Haematologica"},{"key":"2807_CR80","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 2018;78:2449\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3115.","journal-title":"Cancer Res"},{"key":"2807_CR81","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2021-150889","volume":"138","author":"R Boiarsky","year":"2021","unstructured":"Boiarsky R, Haradhvala N, Sklavenitis-Pistofidis R, Mouhieddine TH, Alberge J-B, Zavidij O, Firer D, Anand S, El-Khoury H, Aguet F, et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Blood. 2021;138:2219\u20132219. https:\/\/doi.org\/10.1182\/blood-2021-150889.","journal-title":"Blood"},{"key":"2807_CR82","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ncrna5010013","volume":"5","author":"R Butova","year":"2019","unstructured":"Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R. Long non-coding RNAs in multiple myeloma. Non-Coding RNA. 2019;5:13. https:\/\/doi.org\/10.3390\/ncrna5010013.","journal-title":"Non-Coding RNA"},{"key":"2807_CR83","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.3390\/ijms22094462","volume":"22","author":"N Giannakoulas","year":"2021","unstructured":"Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci. 2021;22:4462. https:\/\/doi.org\/10.3390\/ijms22094462.","journal-title":"Int J Mol Sci"},{"key":"2807_CR84","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood-2023-178534","volume":"142","author":"I Cenzano","year":"2023","unstructured":"Cenzano I, Cocera M, Bantan A, Larrayoz M, Vilas-Zornoza A, San-Martin P, Aguirre-Ruiz P, Ariceta B, Ye J, Alignani D, et al. Comprehensive characterization of the bone marrow microenvironment transcriptional remodeling in the progression from MGUS to smoldering and multiple myeloma. Blood. 2023;142:88. https:\/\/doi.org\/10.1182\/blood-2023-178534.","journal-title":"Blood"},{"key":"2807_CR85","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","volume":"17","author":"L L\u00f3pez-Corral","year":"2011","unstructured":"L\u00f3pez-Corral L, Guti\u00e9rrez NC, Vidriales MB, Mateos MV, Rasillo A, Garc\u00eda-Sanz R, Paiva B, San Miguel JF. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011;17:1692\u2013700. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1066.","journal-title":"Clin Cancer Res"},{"key":"2807_CR86","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.2147\/OTT.S205922","volume":"12","author":"Y Hu","year":"2019","unstructured":"Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. OTT. 2019;12:4075\u201380. https:\/\/doi.org\/10.2147\/OTT.S205922.","journal-title":"OTT"},{"key":"2807_CR87","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91\u2013101. https:\/\/doi.org\/10.1016\/j.ccr.2013.12.015.","journal-title":"Cancer Cell"},{"key":"2807_CR88","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/cancers16020358","volume":"16","author":"M Dragomir","year":"2024","unstructured":"Dragomir M, C\u0103lug\u0103ru O-T, Popescu B, Jardan C, Jardan D, Popescu M, Aposteanu S, B\u0103deli\u021b\u0103 S, Nedelcu G, \u0218erban C, et al. DNA sequencing of CD138 cell population reveals TP53 and RAS-MAPK mutations in multiple myeloma at diagnosis. Cancers (Basel). 2024;16:358. https:\/\/doi.org\/10.3390\/cancers16020358.","journal-title":"Cancers (Basel)"},{"key":"2807_CR89","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood-2024-207609","volume":"144","author":"KJC Lim","year":"2024","unstructured":"Lim KJC, Wellard C, Moore E, Gration B, Augustson B, Mollee P, Zhang J, Wong Doo N, Ringkowski S, Bryant A, et al. Integrating chromosomal 1 abnormalities into the definition of high-risk multiple myeloma: a report from the Australian and New Zealand myeloma and related diseases registry. Blood. 2024;144:1951\u20131951. https:\/\/doi.org\/10.1182\/blood-2024-207609.","journal-title":"Blood"},{"key":"2807_CR90","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1182\/blood-2023-182845","volume":"142","author":"A Vaishnav","year":"2023","unstructured":"Vaishnav A, Khan A, Zhao Q, Bumma N, Cottini F, Umyarova E, Sharma N, Rosko AE, Benson D, Devarakonda S. Deletion 1p at time of diagnosis of multiple myeloma portends inferior outcomes. Blood. 2023;142:1974\u20131974. https:\/\/doi.org\/10.1182\/blood-2023-182845.","journal-title":"Blood"},{"key":"2807_CR91","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1080\/10428194.2016.1272689","volume":"58","author":"R Chakraborty","year":"2017","unstructured":"Chakraborty R, Gertz MA. +1q: amplifying the bad genes in myeloma. Leuk Lymphoma. 2017;58:1771\u20133. https:\/\/doi.org\/10.1080\/10428194.2016.1272689.","journal-title":"Leuk Lymphoma"},{"key":"2807_CR92","doi-asserted-by":"publisher","first-page":"204062072210820","DOI":"10.1177\/20406207221082043","volume":"13","author":"HKK Tang","year":"2022","unstructured":"Tang HKK, Fung CY, Morgan GJ, Kumar S, Siu L, Ip HWA, Yip SF, Lau KNH, Lau CK, Lee H, et al. The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 Gain. Ther Adv Hematol. 2022;13:20406207221082044. https:\/\/doi.org\/10.1177\/20406207221082043.","journal-title":"Ther Adv Hematol"},{"key":"2807_CR93","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/blood-2024-205523","volume":"144","author":"J-B Alberge","year":"2024","unstructured":"Alberge J-B, Dutta AK, Poletti A, Priebe O, Coorens THH, Lightbody ED, Toenges R, Loinaz X, Wallin S, Dunford A, et al. Novel non-coding candidate drivers of multiple myeloma linked to plasma cell tumor biology and B cell development. Blood. 2024;144:1894\u20131894. https:\/\/doi.org\/10.1182\/blood-2024-205523.","journal-title":"Blood"},{"key":"2807_CR94","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood-2018-190","volume":"132","author":"MK Samur","year":"2018","unstructured":"Samur MK, Chakraborty C, Szalat R, Aktas Samur A, Fulciniti M, Lopez MA, Shammas MA, Richardson P, Magrangeas F, Minvielle S, et al. Landscape of recurrent mutations in non-coding genome with functional implications in newly-diagnosed multiple myeloma. Blood. 2018;132:190\u2013190. https:\/\/doi.org\/10.1182\/blood-2018-190.","journal-title":"Blood"},{"key":"2807_CR95","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2024-211012","volume":"144","author":"P Blaney","year":"2024","unstructured":"Blaney P, Maclachlan KH, Papadimitriou M, Mikulasova A, Gagler DC, Braunstein MJ, Lahoud OB, Kaminetzky D, Wang Y, Liu S, et al. Mutationally enriched regions of the non-coding genome harbor functionally impactful mutations that dysregulate key genes involved in multiple myeloma pathogenesis. Blood. 2024;144:4655. https:\/\/doi.org\/10.1182\/blood-2024-211012.","journal-title":"Blood"},{"key":"2807_CR96","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1038\/s41375-018-0103-3","volume":"32","author":"PH Hoang","year":"2018","unstructured":"Hoang PH, Dobbins SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, Houlston RS. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 2018;32:2459\u201370. https:\/\/doi.org\/10.1038\/s41375-018-0103-3.","journal-title":"Leukemia"},{"key":"2807_CR97","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1182\/blood-2018-99-118845","volume":"132","author":"M Fulciniti","year":"2018","unstructured":"Fulciniti M, Lopez MA, Aktas Samur A, Morelli E, Avet-Loiseau H, Samur MK, Munshi N. Dysregulation of splicing in multiple myeloma: the splicing factor SRSF1 supports MM cell proliferation via splicing control. Blood. 2018;132:4500\u20134500. https:\/\/doi.org\/10.1182\/blood-2018-99-118845.","journal-title":"Blood"},{"key":"2807_CR98","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1182\/blood.V126.23.726.726","volume":"126","author":"M Fulciniti","year":"2015","unstructured":"Fulciniti M, Samur MK, Rashid NU, Bandi RL, Bhasin M, Parmigiani G, Anderson KC, Munshi NC. Functional and clinical impact of splicing factor dysregulation in multiple myeloma. Blood. 2015;126:726\u2013726. https:\/\/doi.org\/10.1182\/blood.V126.23.726.726.","journal-title":"Blood"},{"key":"2807_CR99","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4161\/rna.23343","volume":"10","author":"T Shimokawa","year":"2013","unstructured":"Shimokawa T, Rahman MF-U, Tostar U, Sonkoly E, St\u00e5hle M, Pivarcsi A, Palaniswamy R, Zaphiropoulos PG. RNA editing of the GLI1 transcription factor modulates the output of hedgehog signaling. RNA Biol. 2013;10:321\u201333. https:\/\/doi.org\/10.4161\/rna.23343.","journal-title":"RNA Biol"},{"key":"2807_CR100","doi-asserted-by":"publisher","first-page":"11790","DOI":"10.3390\/ijms222111790","volume":"22","author":"I Sahin","year":"2021","unstructured":"Sahin I, George A, Seyhan AA. Therapeutic targeting of alternative RNA splicing in gastrointestinal malignancies and other cancers. IJMS. 2021;22:11790. https:\/\/doi.org\/10.3390\/ijms222111790.","journal-title":"IJMS"},{"key":"2807_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175380","volume":"941","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Roshanzamir SM, Paskeh MDA, Karimian SS, Mahdavi MS, Kheirabad SK, Naeemi S, Taheriazam A, Salimimoghaddam S, Entezari M, et al. Non-coding RNAs and exosomal ncRNAs in multiple myeloma: an emphasis on molecular pathways. Eur J Pharmacol. 2023;941: 175380. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175380.","journal-title":"Eur J Pharmacol"},{"key":"2807_CR102","doi-asserted-by":"publisher","first-page":"713","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.02.061","volume":"28","author":"X-Q Sun","year":"2020","unstructured":"Sun X-Q, Bi F-Q, Cui X. Reaserch progress on non-coding RNA in Multiple myeloma\u2013review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28:713\u20136. https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.02.061.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2807_CR103","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-019-1071-9","volume":"38","author":"Y Feng","year":"2019","unstructured":"Feng Y, Zhang L, Wu J, Khadka B, Fang Z, Gu J, Tang B, Xiao R, Pan G, Liu J. CircRNA Circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p\/MAPK4 pathway. J Exp Clin Cancer Res. 2019;38:54. https:\/\/doi.org\/10.1186\/s13046-019-1071-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"2807_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107593","volume":"146","author":"M Lei","year":"2024","unstructured":"Lei M, Liang J, Guo K, Tang L, He Y, Wu X. Roles of noncoding RNAs in multiple myeloma. Leuk Res. 2024;146: 107593. https:\/\/doi.org\/10.1016\/j.leukres.2024.107593.","journal-title":"Leuk Res"},{"key":"2807_CR105","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3109\/10428199909058473","volume":"34","author":"M Ng","year":"1999","unstructured":"Ng M, Wong M, Lo K. DNA methylation changes and multiple myeloma. Leuk Lymphoma. 1999;34:463\u201372. https:\/\/doi.org\/10.3109\/10428199909058473.","journal-title":"Leuk Lymphoma"},{"key":"2807_CR106","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood.V116.21.784.784","volume":"116","author":"C Heuck","year":"2010","unstructured":"Heuck C, Mehta J, Tariman J, Pulliam N, Yu Y, Bhagat T, Nischal S, Meagher R, Hu CY, Verma A, et al. Epigenomic profiling of multiple myeloma shows widespread stage specific alterations in DNA methylation that occur early during myelomagenesis. Blood. 2010;116:784\u2013784. https:\/\/doi.org\/10.1182\/blood.V116.21.784.784.","journal-title":"Blood"},{"key":"2807_CR107","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.3892\/etm.2017.4274","volume":"13","author":"D Mart\u00ednez-Ba\u00f1os","year":"2017","unstructured":"Mart\u00ednez-Ba\u00f1os D, S\u00e1nchez-Hern\u00e1ndez B, Jim\u00e9nez G, Barrera-Lumbreras G, Barrales-Ben\u00edtez O. Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission. Exp Ther Med. 2017;13:2442\u201350. https:\/\/doi.org\/10.3892\/etm.2017.4274.","journal-title":"Exp Ther Med"},{"key":"2807_CR108","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood.V124.21.2032.2032","volume":"124","author":"X Agirre","year":"2014","unstructured":"Agirre X, Castellano G, Pascual M, Health S, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, et al. Whole-genome epigenomic analysis in multiple myeloma reveals DNA hypermethylation of B-cell specific enhancers. Blood. 2014;124:2032\u20132032. https:\/\/doi.org\/10.1182\/blood.V124.21.2032.2032.","journal-title":"Blood"},{"key":"2807_CR109","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1007\/s11033-021-06813-z","volume":"48","author":"S Pehlivan","year":"2021","unstructured":"Pehlivan S, Serin I, Nursal AF, Oyaci Y, Gundes I, Pehlivan M. What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma? Mol Biol Rep. 2021;48:7875\u201382. https:\/\/doi.org\/10.1007\/s11033-021-06813-z.","journal-title":"Mol Biol Rep"},{"key":"2807_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-018-0119-y","volume":"8","author":"H Ohguchi","year":"2018","unstructured":"Ohguchi H, Hideshima T, Anderson KC. The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018;8:83. https:\/\/doi.org\/10.1038\/s41408-018-0119-y.","journal-title":"Blood Cancer J"},{"key":"2807_CR111","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00277-005-0006-z","volume":"84","author":"A Gozzini","year":"2005","unstructured":"Gozzini A, Santini V. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol. 2005;84:54\u201360. https:\/\/doi.org\/10.1007\/s00277-005-0006-z.","journal-title":"Ann Hematol"},{"key":"2807_CR112","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1074\/mcp.M115.053819","volume":"15","author":"Y Zheng","year":"2016","unstructured":"Zheng Y, Fornelli L, Compton PD, Sharma S, Canterbury J, Mullen C, Zabrouskov V, Fellers RT, Thomas PM, Licht JD, et al. Unabridged analysis of human histone H3 by differential top-down mass spectrometry reveals hypermethylated proteoforms from MMSET\/NSD2 overexpression. Mol Cell Proteomics. 2016;15:776\u201390. https:\/\/doi.org\/10.1074\/mcp.M115.053819.","journal-title":"Mol Cell Proteomics"},{"key":"2807_CR113","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.3390\/cancers13164069","volume":"13","author":"J Sch\u00fctt","year":"2021","unstructured":"Sch\u00fctt J, N\u00e4gler T, Schenk T, Brioli A. Investigating the interplay between myeloma cells and bone marrow stromal cells in the development of drug resistance: dissecting the role of epigenetic modifications. Cancers. 2021;13:4069. https:\/\/doi.org\/10.3390\/cancers13164069.","journal-title":"Cancers"},{"key":"2807_CR114","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1038\/s41467-019-12811-4","volume":"10","author":"P Lhoumaud","year":"2019","unstructured":"Lhoumaud P, Badri S, Rodriguez-Hernaez J, Sakellaropoulos T, Sethia G, Kloetgen A, Cornwell M, Bhattacharyya S, Ay F, Bonneau R, et al. NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains. Nat Commun. 2019;10:4843. https:\/\/doi.org\/10.1038\/s41467-019-12811-4.","journal-title":"Nat Commun"},{"key":"2807_CR115","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-017-01793-w","volume":"2017","author":"P Wu","year":"1937","unstructured":"Wu P, Li T, Li R, Jia L, Zhu P, Liu Y, Chen Q, Tang D, Yu Y, Li C. 3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations. Nat Commun. 1937;2017:8. https:\/\/doi.org\/10.1038\/s41467-017-01793-w.","journal-title":"Nat Commun"},{"key":"2807_CR116","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2023-181018","volume":"142","author":"E Varlet","year":"2023","unstructured":"Varlet E, Alaterre E, Thomas M, De Boussac H, Vincent L, Cartron G, Herbaux C, Bret C, Herviou L, Martinez AM, et al. Epigenetic modifiers MMSET and EZH2 physically interact and cooperate to support multiple myeloma pathophysiology. Blood. 2023;142:1964\u20131964. https:\/\/doi.org\/10.1182\/blood-2023-181018.","journal-title":"Blood"},{"key":"2807_CR117","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, Venglar O, Muronova L, Broskevicova L, Nenarokov S, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38:1323\u201333. https:\/\/doi.org\/10.1038\/s41375-024-02206-w.","journal-title":"Leukemia"},{"key":"2807_CR118","doi-asserted-by":"publisher","first-page":"67","DOI":"10.17650\/1818-8346-2022-17-4-67-80","volume":"17","author":"MV Firsova","year":"2022","unstructured":"Firsova MV, Risinskaya NV, Solovev MV, Obukhova TN, Kislitsyna MA, Nikulina EE, Yakutik IA, Abramova TV, Sudarikov AB, Kovrigina AM, et al. Multiple myeloma with extramedullary plasmacytoma: pathogenesis and clinical case. Onkogematologi\u00e2. 2022;17:67\u201380. https:\/\/doi.org\/10.17650\/1818-8346-2022-17-4-67-80.","journal-title":"Onkogematologi\u00e2"},{"key":"2807_CR119","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.005","volume":"17","author":"U Testa","year":"2024","unstructured":"Testa U, Leone GGM. Plasmacell neoplasms with spreading in the blood and tissues: extramedullary myeloma disease a rare aggressive form of multiple myeloma (First of Two Parts): Extra Medullary Myeloma. Mediterr J Hematol Infect Dis. 2024;17: e2025005. https:\/\/doi.org\/10.4084\/MJHID.2025.005.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2807_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70036","volume":"43","author":"J Gregorova","year":"2025","unstructured":"Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M, Radova L, Pospichalova V, Sladecek S, Hyzdalova M, et al. MicroRNA profiling of bone marrow plasma extracellular vesicles in multiple myeloma, extramedullary disease, and plasma cell leukemia. Hematol Oncol. 2025;43: e70036. https:\/\/doi.org\/10.1002\/hon.70036.","journal-title":"Hematol Oncol"},{"key":"2807_CR121","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.3390\/ijms232314765","volume":"23","author":"M Vlachov\u00e1","year":"2022","unstructured":"Vlachov\u00e1 M, Gregorov\u00e1 J, Vychytilov\u00e1-Faltejskov\u00e1 P, Gab\u0142o NA, Radov\u00e1 L, Posp\u00ed\u0161ilov\u00e1 L, Alm\u00e1\u0161i M, \u0160tork M, Knechtov\u00e1 Z, Mina\u0159\u00edk J, et al. Involvement of small non-coding RNA and cell antigens in pathogenesis of extramedullary multiple myeloma. IJMS. 2022;23:14765. https:\/\/doi.org\/10.3390\/ijms232314765.","journal-title":"IJMS"},{"key":"2807_CR122","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, Orloff G, Jakubowiak A, Niesvizky R, Liles D, et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024;56:1878\u201389. https:\/\/doi.org\/10.1038\/s41588-024-01853-0.","journal-title":"Nat Genet"},{"key":"2807_CR123","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/blood.V128.22.194.194","volume":"128","author":"JJ Keats","year":"2016","unstructured":"Keats JJ, Speyer G, Christofferson A, Legendre C, Aldrich J, Russell M, Cuyugan L, Adkins J, Blanski A, Hodges M, et al. Molecular predictors of outcome and drug response in multiple myeloma: an interim analysis of the Mmrf CoMMpass study. Blood. 2016;128:194\u2013194. https:\/\/doi.org\/10.1182\/blood.V128.22.194.194.","journal-title":"Blood"},{"key":"2807_CR124","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2018-99-118617","volume":"132","author":"S Skerget","year":"2018","unstructured":"Skerget S, Penaherrera D, Aldrich J, Nasser S, Christofferson A, Legendre C, Boateng M, Cuyugan L, Adkins J, Tassone E, et al. Analysis of sequential patient samples from the Mmrf CoMMpass study identifies a high risk progression phenotype. Blood. 2018;132:111\u2013111. https:\/\/doi.org\/10.1182\/blood-2018-99-118617.","journal-title":"Blood"},{"key":"2807_CR125","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/hematolrep17020018","volume":"17","author":"L Pratiwi","year":"2025","unstructured":"Pratiwi L, Mashudi FH, Ningtyas MC, Sutanto H, Romadhon PZ. Genetic profiling of acute and chronic leukemia via next-generation sequencing: current insights and future perspectives. Hematol Rep. 2025;17:18. https:\/\/doi.org\/10.3390\/hematolrep17020018.","journal-title":"Hematol Rep"},{"key":"2807_CR126","doi-asserted-by":"publisher","unstructured":"Lomas, O.C.; Gooding, S.; Cabes, M.; Dreau, H.; Wilson, E.; Polzella, P.; Genomics England Research Consortium; Ramasamy, K.; Hamblin, A.D. Validation of clinical\u2010grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly\u2010diagnosed multiple myeloma patients: a pilot study from the 100,000 genomes project. eJHaem 2021, 2, 809\u2013812, https:\/\/doi.org\/10.1002\/jha2.276.","DOI":"10.1002\/jha2.276"},{"key":"2807_CR127","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2019-125145","volume":"134","author":"O Lomas","year":"2019","unstructured":"Lomas O, Gooding S, Ramasamy K, Hamblin A, Cabes M, Dreau HM-P, Wilson E. Clinical-grade whole genome sequencing reproduces FISH cytogenetics and provides actionable data in newly diagnosed myeloma\u2014a pilot study from the UK 100,000 genomes project. Blood. 2019;134:3062\u20133062. https:\/\/doi.org\/10.1182\/blood-2019-125145.","journal-title":"Blood"},{"key":"2807_CR128","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1538-7445.AM2018-434","volume":"78","author":"A Sosinsky","year":"2018","unstructured":"Sosinsky A, Antoniou P, Ambrose J, Mijuskovic M, Rueda-Martin A, Perez-Gil D, Serra E, Henderson S, Hamblin A, Schuh A, et al. Abstract 434: 100,000 genomes project: cancer program. Cancer Res. 2018;78:434\u2013434. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-434.","journal-title":"Cancer Res"},{"key":"2807_CR129","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1158\/1538-7445.AM2023-775","volume":"83","author":"M Dang","year":"2023","unstructured":"Dang M, Kunacheewa C, Lee HC, Patel KK, Thomas SK, Becnel M, Weber DM, Lin P, Berkova Z, Huang M, et al. Abstract 775: integrative genomic and transcriptomic profiling of myeloma precursors in a prospective longitudinal observational study (ORIGIN). Can Res. 2023;83:775. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-775.","journal-title":"Can Res"},{"key":"2807_CR130","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2023-184900","volume":"142","author":"J-B Alberge","year":"2023","unstructured":"Alberge J-B, Dutta AK, Lightbody ED, Poletti A, Wallin S, Dunford A, Coorens T, Loinaz X, Boehner CJ, Su NK, et al. Genome sequencing to discover drivers of clonal expansion in smoldering multiple myeloma. Blood. 2023;142:4143\u20134143. https:\/\/doi.org\/10.1182\/blood-2023-184900.","journal-title":"Blood"},{"key":"2807_CR131","doi-asserted-by":"publisher","first-page":"1020011","DOI":"10.3389\/fonc.2022.1020011","volume":"12","author":"M Mejia Saldarriaga","year":"2022","unstructured":"Mejia Saldarriaga M, Darwiche W, Jayabalan D, Monge J, Rosenbaum C, Pearse RN, Niesvizky R, Bustoros M. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Front Oncol. 2022;12:1020011. https:\/\/doi.org\/10.3389\/fonc.2022.1020011.","journal-title":"Front Oncol"},{"key":"2807_CR132","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood.V128.22.2088.2088","volume":"128","author":"N Bolli","year":"2016","unstructured":"Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Samur MK, Tarpey P, Davies H, Martincorena I, et al. Whole genome sequencing of unique paired SMM\/MGUS progressing to MM samples reveals a genomic landscape with diverse evolutionary pattern. Blood. 2016;128:2088\u20132088. https:\/\/doi.org\/10.1182\/blood.V128.22.2088.2088.","journal-title":"Blood"},{"key":"2807_CR133","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.20.00437","volume":"38","author":"M Bustoros","year":"2020","unstructured":"Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai Y-T, Anand S, Mouhieddine TH, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. JCO. 2020;38:2380\u20139. https:\/\/doi.org\/10.1200\/JCO.20.00437.","journal-title":"JCO"},{"key":"2807_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2025.104268","volume":"54","author":"C Saade","year":"2025","unstructured":"Saade C, Ghobrial IM. Updates on mechanisms of disease progression in precursor myeloma: monoclonal gammopathy of undermined significance and smoldering myeloma. La Presse M\u00e9dicale. 2025;54: 104268. https:\/\/doi.org\/10.1016\/j.lpm.2025.104268.","journal-title":"La Presse M\u00e9dicale"},{"key":"2807_CR135","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2018-99-115046","volume":"132","author":"M Rahmat","year":"2018","unstructured":"Rahmat M, Haradhvala N, Sklavenitis-Pistofidis R, Park J, Huynh D, Bustoros M, Berrios B, Reidy M, Perilla-Glen A, Rivotto B, et al. Dissecting the epigenetic landscape of smoldering, newly diagnosed and relapsed multiple myeloma revealed IRAK3 as a marker of disease progression. Blood. 2018;132:3896\u20133896. https:\/\/doi.org\/10.1182\/blood-2018-99-115046.","journal-title":"Blood"},{"key":"2807_CR136","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"M-V Mateos","year":"2020","unstructured":"Mateos M-V, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102. https:\/\/doi.org\/10.1038\/s41408-020-00366-3.","journal-title":"Blood Cancer J"},{"key":"2807_CR137","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2023-180315","volume":"142","author":"T Akhlaghi","year":"2023","unstructured":"Akhlaghi T, Nemirovsky D, Maclachlan KH, Korde N, Mailankody S, Lesokhin A, Hassoun H, Patel D, Shah UA, Tan C, et al. Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma. Blood. 2023;142:877\u2013877. https:\/\/doi.org\/10.1182\/blood-2023-180315.","journal-title":"Blood"},{"key":"2807_CR138","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"key":"2807_CR139","unstructured":"Mayo Stratification of Myeloma and Risk-Adapted Therapy mSMART 4.0: Classification of Active MM. 2024."},{"key":"2807_CR140","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/cncr.34893","volume":"129","author":"TM Schmidt","year":"2023","unstructured":"Schmidt TM. Making a case for Del(1p) as a high-risk abnormality in multiple myeloma. Cancer. 2023;129:2450\u20132. https:\/\/doi.org\/10.1002\/cncr.34893.","journal-title":"Cancer"},{"key":"2807_CR141","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1182\/blood-2019-129739","volume":"134","author":"C Du","year":"2019","unstructured":"Du C, Gang A, Xu Y, Mao X, Yan Y, Liu J, Fan H, Sui W, Deng S, Zengjun L, et al. 1q21 gain may challenge the role of t(4;14) as an adverse prognostic marker of multiple myeloma. Blood. 2019;134:4343\u20134343. https:\/\/doi.org\/10.1182\/blood-2019-129739.","journal-title":"Blood"},{"key":"2807_CR142","doi-asserted-by":"publisher","first-page":"2377850","DOI":"10.1080\/16078454.2024.2377850","volume":"29","author":"X Tang","year":"2024","unstructured":"Tang X, Chen Y. Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma. Hematology. 2024;29:2377850. https:\/\/doi.org\/10.1080\/16078454.2024.2377850.","journal-title":"Hematology"},{"key":"2807_CR143","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.pathol.2023.12.415","volume":"56","author":"S Sreedharanunni","year":"2024","unstructured":"Sreedharanunni S, Singla S, Balakrishnan A, Singh A, Jamwal M, Singh N, Singh C, Jandial A, Lad D, Sharma P, et al. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma. Pathology. 2024;56:556\u201364. https:\/\/doi.org\/10.1016\/j.pathol.2023.12.415.","journal-title":"Pathology"},{"key":"2807_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.61","volume":"8","author":"G Mellgard","year":"2024","unstructured":"Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty R. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere. 2024;8: e61. https:\/\/doi.org\/10.1002\/hem3.61.","journal-title":"HemaSphere"},{"key":"2807_CR145","doi-asserted-by":"publisher","first-page":"25254","DOI":"10.18632\/oncotarget.25402","volume":"9","author":"M Wennmann","year":"2018","unstructured":"Wennmann M, Kintzel\u00e9 L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor H-U, Merz M, Hillengass J, et al. Volumetry based biomarker speed of growth: quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget. 2018;9:25254\u201364. https:\/\/doi.org\/10.18632\/oncotarget.25402.","journal-title":"Oncotarget"},{"key":"2807_CR146","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/ajh.27364","volume":"99","author":"S Kumar","year":"2024","unstructured":"Kumar S, Rajkumar SV, Jevremovic D, Kyle RA, Shifrin Y, Nguyen M, Husain Z, Alikhah A, Jafari A, Mai S, et al. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. American J Hematol. 2024;99:1532\u20139. https:\/\/doi.org\/10.1002\/ajh.27364.","journal-title":"American J Hematol"},{"key":"2807_CR147","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1:493\u2013506. https:\/\/doi.org\/10.1038\/s43018-020-0053-3.","journal-title":"Nat Cancer"},{"key":"2807_CR148","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1182\/blood-2018-99-118281","volume":"132","author":"M Bhutani","year":"2018","unstructured":"Bhutani M, Foureau DM, Steuerwald NM, Trufan S, Guo F, Rigby K, Tjaden E, Hamilton A, Leonidas M, Berlin A, et al. Molecular characterization by immune profiling of paired blood and bone marrow in multiple myeloma and its precursor states. Blood. 2018;132:4461\u20134461. https:\/\/doi.org\/10.1182\/blood-2018-99-118281.","journal-title":"Blood"},{"key":"2807_CR149","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1182\/blood-2024-206540","volume":"144","author":"J Tsuji","year":"2024","unstructured":"Tsuji J, Lightbody ED, Sklavenitis-Pistofidis R, Wu T, Agius MP, Firer DT, Rahmat M, Barr H, Konishi Y, Dutta AK, et al. Single-cell profiling of ~1.7 million plasma cells across >250 individuals reveals transcriptional signatures of progression and clonal expansion in multiple myeloma and its precursor stages. Blood. 2024;144:4637\u20134637. https:\/\/doi.org\/10.1182\/blood-2024-206540.","journal-title":"Blood"},{"key":"2807_CR150","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14:194. https:\/\/doi.org\/10.1038\/s41408-024-01172-x.","journal-title":"Blood Cancer J"},{"key":"2807_CR151","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2141.2009.07976.x","volume":"148","author":"EM Smith","year":"2010","unstructured":"Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2010;148:702\u201313. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07976.x.","journal-title":"Br J Haematol"},{"key":"2807_CR152","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1871529X11313010003","volume":"13","author":"O Fuchs","year":"2013","unstructured":"Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. CHDDT. 2013;13:16\u201334. https:\/\/doi.org\/10.2174\/1871529X11313010003.","journal-title":"CHDDT"},{"key":"2807_CR153","doi-asserted-by":"publisher","first-page":"21930","DOI":"10.18632\/oncotarget.25128","volume":"9","author":"T Harding","year":"2018","unstructured":"Harding T, Swanson J, Van Ness B. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes. Oncotarget. 2018;9:21930\u201342. https:\/\/doi.org\/10.18632\/oncotarget.25128.","journal-title":"Oncotarget"},{"key":"2807_CR154","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.1038\/sj.onc.1206814","volume":"22","author":"R Claus","year":"2003","unstructured":"Claus R, L\u00fcbbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003;22:6489\u201396. https:\/\/doi.org\/10.1038\/sj.onc.1206814.","journal-title":"Oncogene"},{"key":"2807_CR155","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.CHROMEPI15-IA23","author":"J-PJ Issa","year":"2016","unstructured":"Issa J-PJ. Abstract IA23: multiple targetable pathways for epigenetic therapy. Cancer Res. 2016. https:\/\/doi.org\/10.1158\/1538-7445.CHROMEPI15-IA23.","journal-title":"Cancer Res"},{"key":"2807_CR156","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28:1776\u201387. https:\/\/doi.org\/10.1093\/annonc\/mdx157.","journal-title":"Ann Oncol"},{"key":"2807_CR157","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5937\/hpimj1402083S","volume":"1","author":"KM Stankov","year":"2014","unstructured":"Stankov KM, Pavlovi\u0107 NM, Mikov MM. Epigenetic therapy of cancer. Hosp Pharm Int Multi J. 2014;1:83.","journal-title":"Hosp Pharm Int Multi J"},{"key":"2807_CR158","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1182\/blood-2021-148543","volume":"138","author":"F Sun","year":"2021","unstructured":"Sun F, Cheng Y, Peng B, Xu H, Van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. Bispecific CAR-T cells targeting both BCMA and CD24: a potentially treatment approach for multiple myeloma. Blood. 2021;138:2802\u20132802. https:\/\/doi.org\/10.1182\/blood-2021-148543.","journal-title":"Blood"},{"key":"2807_CR159","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-LB188","author":"G Agrahari","year":"2023","unstructured":"Agrahari G, Liang W, O\u2019Callaghan K, Zhang K, Jiang N, Jin X, Feng R, Nguyen J, Hassan S, Luu A, et al. Abstract LB188: discovery and development of fully human TACI\/BCMA bispecific armored CAR for the treatment of relapsed\/refractory multiple myeloma. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-LB188.","journal-title":"Cancer Res"},{"key":"2807_CR160","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood-2023-190019","volume":"142","author":"CTR Vegivinti","year":"2023","unstructured":"Vegivinti CTR, Santhi Lawrence Alexander, J., Liu, L., Keesari, P.R., Thakur, R., Hammami, M.B., Kapu, V., Pericherla, S., Gopireddy, M.M.R., Poojary, N, et al. Efficacy of bispecific antibodies Vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: a systematic review and meta-analysis. Blood. 2023;142:1994\u20131994. https:\/\/doi.org\/10.1182\/blood-2023-190019.","journal-title":"Blood"},{"key":"2807_CR161","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Toenges R, Bertamini L, Alberge J-B, Ghobrial IM. New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer. 2024;24:867\u201386. https:\/\/doi.org\/10.1038\/s41568-024-00755-x.","journal-title":"Nat Rev Cancer"},{"key":"2807_CR162","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3324\/haematol.2019.235424","volume":"106","author":"A Michael","year":"2020","unstructured":"Michael A, Bauer; Cody Ashby; Christopher Wardell; Eileen M. Boyle; Maria Ortiz; Erin Flynt; Anjan Thakurta; Gareth Morgan; Brian A. Walker. Differential RNA splicing as a potentially important driver mechanism in multiple myeloma. Haematol. 2020;106:736\u201345. https:\/\/doi.org\/10.3324\/haematol.2019.235424.","journal-title":"Haematol"},{"key":"2807_CR163","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/dna.2016.3575","volume":"36","author":"L Goldberg","year":"2017","unstructured":"Goldberg L, Abutbul-Amitai M, Paret G, Nevo-Caspi Y. Alternative splicing of STAT3 is affected by RNA editing. DNA Cell Biol. 2017;36:367\u201376. https:\/\/doi.org\/10.1089\/dna.2016.3575.","journal-title":"DNA Cell Biol"},{"key":"2807_CR164","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood.V124.21.638.638","volume":"124","author":"N Rashid","year":"2014","unstructured":"Rashid N, Minvielle S, Magrangeas F, Samur MK, Clynen A, Sperling A, Tai Y-T, Fulciniti M, Richardson PG, Attal M, et al. Alternative splicing is a frequent event and impacts clinical outcome in myeloma: a large RNA-seq data analysis of newly-diagnosed myeloma patients. Blood. 2014;124:638\u2013638. https:\/\/doi.org\/10.1182\/blood.V124.21.638.638.","journal-title":"Blood"},{"key":"2807_CR165","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood.V128.22.356.356","volume":"128","author":"A Aktas Samur","year":"2016","unstructured":"Aktas Samur A, Samur MK, Minvielle S, Magrangeas F, Fulciniti M, Szalat R, Richardson PG, Anderson KC, Attal M, Moreau P, et al. A detailed alternate splicing landscape in multiple myeloma with significant potential biological and clinical implications. Blood. 2016;128:356\u2013356. https:\/\/doi.org\/10.1182\/blood.V128.22.356.356.","journal-title":"Blood"},{"key":"2807_CR166","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood.V118.21.1810.1810","volume":"118","author":"W Song","year":"2011","unstructured":"Song W, Hu Y, Yang G, Shah PK, Shan W, Tai Y-T, Li Y, Minvielle S, Avet-Loiseau H, Anderson KC, et al. Alternate splicing factor Fox2 affects growth and survival of multiple myeloma cells. Blood. 2011;118:1810\u20131810. https:\/\/doi.org\/10.1182\/blood.V118.21.1810.1810.","journal-title":"Blood"},{"key":"2807_CR167","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/16078454.2021.1872275","volume":"26","author":"Y Yin","year":"2021","unstructured":"Yin Y, Yang W, Zhang L, Liu K, Luo Z. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma. Hematology. 2021;26:160\u20139. https:\/\/doi.org\/10.1080\/16078454.2021.1872275.","journal-title":"Hematology"},{"key":"2807_CR168","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/wsbm.89","volume":"2","author":"A Sharma","year":"2010","unstructured":"Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, Verma A. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. WIREs Mech Dis. 2010;2:654\u201369. https:\/\/doi.org\/10.1002\/wsbm.89.","journal-title":"WIREs Mech Dis"},{"key":"2807_CR169","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/cancers12102996","volume":"12","author":"C Caprio","year":"2020","unstructured":"Caprio C, Sacco A, Giustini V, Roccaro AM. Epigenetic aberrations in multiple myeloma. Cancers. 2020;12:2996. https:\/\/doi.org\/10.3390\/cancers12102996.","journal-title":"Cancers"},{"key":"2807_CR170","first-page":"124","volume":"73","author":"Y Terui","year":"2015","unstructured":"Terui Y. The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma. Nihon Rinsho. 2015;73:124\u20139.","journal-title":"Nihon Rinsho"},{"key":"2807_CR171","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.7150\/thno.54453","volume":"12","author":"E Alaterre","year":"2022","unstructured":"Alaterre E, Ovejero S, Herviou L, De Boussac H, Papadopoulos G, Kulis M, Boireau S, Robert N, Requirand G, Bruyer A, et al. Comprehensive characterization of the epigenetic landscape in multiple myeloma. Theranostics. 2022;12:1715\u201329. https:\/\/doi.org\/10.7150\/thno.54453.","journal-title":"Theranostics"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02807-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02807-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:39:16Z","timestamp":1751531956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02807-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":171,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2807"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02807-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}],"article-number":"234"}}